Howard Hughes Medical Institute

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Celsius Therapeutics Names Scientific Advisers

Retrieved on: 
Thursday, September 22, 2022

Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.

Key Points: 
  • Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.
  • As Celsius prepares to advance our first programs into the clinic, we are entering a transitional point in our evolution, said Tariq Kassum, M.D., President and CEO of Celsius.
  • Director, Crohns and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami Miller School of Medicine.
  • Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale.

ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

Retrieved on: 
Tuesday, September 20, 2022

STING agonist in combination with immune checkpoint inhibitors (ICI) and other therapies such as radiotherapy can mobilize and coordinate a patients immune system against cancer.

Key Points: 
  • STING agonist in combination with immune checkpoint inhibitors (ICI) and other therapies such as radiotherapy can mobilize and coordinate a patients immune system against cancer.
  • We are delighted and honored to receive this grant from CPRIT which will support the continued clinical development of IMSA101.
  • ImmuneSensor is a world leader in the cGAS-STING pathway, based on groundbreaking discoveries by Dr. Zhijian James Chen at the University of Texas Southwestern Medical Center (UTSW).
  • ImmuneSensor Therapeutics Inc. (ImmuneSensor) is a private clinical stage biotechnology company dedicated to harnessing innate immunity to treat cancer and autoimmune diseases.

Infectious Disease Expert Pardis Sabeti, M.D., Ph.D. Joins Board of The 221b Foundation

Retrieved on: 
Thursday, September 15, 2022

"CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.

Key Points: 
  • "CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.
  • Pardis has been a fierce global health advocate for her entire career, and will provide invaluable counsel as we deliver on our mission."
  • Through donations of equipment and resources, The 221b Foundation provided much needed support to help Nepal stem the spread of COVID-19 and bolster the countries testing strategy.
  • The Foundation provides global health partners with access to Sherlock Biosciences' products and IP through distribution and licensing.

Impossible Foods Introduces Impossible™ Bowls — New Plant-Based Meals in the Frozen Aisle

Retrieved on: 
Friday, September 2, 2022

California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., launched its latest food concept in the frozen aisle this week with a new lineup of single-serve frozen entrees: Impossible Bowls delicious plant-based meals ready in minutes.

Key Points: 
  • California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., launched its latest food concept in the frozen aisle this week with a new lineup of single-serve frozen entrees: Impossible Bowls delicious plant-based meals ready in minutes.
  • Teriyaki Impossible Chicken: Seasoned Impossible Chicken, juicy diced pineapple and peas & carrots tossed in a tangy teriyaki glaze, served over white rice.
  • Chili Mac with Impossible Pork: Classic elbow macaroni tossed with Impossible Pork and a hearty chili-style sauce.
  • Earlier this year, Impossible also introduced frozen Impossible Sausage Patties and Impossible Wild Nuggies in February 2022, followed shortly by Impossible Sausage Links in March 2022.

Foghorn Therapeutics Announces Change to Board of Directors

Retrieved on: 
Wednesday, August 31, 2022

In accordance with HHMIs rules, she has resigned from Foghorns Board of Directors, effective August 31, 2022.

Key Points: 
  • In accordance with HHMIs rules, she has resigned from Foghorns Board of Directors, effective August 31, 2022.
  • Dr. Kadoch has become Scientific Advisor to the Board and will continue to participate on Foghorns Scientific Advisory Board.
  • I am excited to continue working with the Board and Company as Scientific Advisor to the Board, said Dr. Kadoch.
  • Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, I want to thank Cigall for her significant contributions to Foghorn as a co-founder and founding Board member.

Harbor ETF Trust and Harbor Funds Expands Boards of Trustees with Landis Zimmerman Appointment

Retrieved on: 
Thursday, August 25, 2022

In a continued effort to add creative innovation and durable value to their investment solutions and talent, the Boards of Trustees of Harbor ETF Trust and Harbor Funds have appointed Landis Zimmerman to serve on the Boards as an independent Trustee.

Key Points: 
  • In a continued effort to add creative innovation and durable value to their investment solutions and talent, the Boards of Trustees of Harbor ETF Trust and Harbor Funds have appointed Landis Zimmerman to serve on the Boards as an independent Trustee.
  • Zimmerman brings to Harbor ETF Trust and Harbor Funds decades of experience investing on behalf of prominent institutions.
  • Talent continues to be one of our critical priorities at Harbor, stated Harbor ETF Trust and Harbor Funds Chairman Charles F. McCain.
  • On behalf of our Boards of Trustees and growing number of associates, we are pleased to have Landis join our Boards.

Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Retrieved on: 
Monday, August 15, 2022

Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.

Key Points: 
  • Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.
  • Monod was founded in November 2021 from technology developed at David Bakers lab at the University of Washington Institute for Protein Design.
  • Our partnership with Monod Bio reflects our commitment to back extraordinary teams unlocking breakthrough innovation at the intersection of technology and life sciences.
  • Monod Bio's innovative biosensor platform technology uses computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and cost-effective analytical assays.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).

Nkarta Announces Key Senior Leadership Team Appointments

Retrieved on: 
Monday, July 25, 2022

Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.

Key Points: 
  • Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.
  • Dr. Brandenberger joined Nkarta in April 2018 and most recently served as Senior Vice President, Technical Operations.
  • Ms. Li joined Nkarta in November 2019 as Senior Vice President, Finance to lead the companys financial management, treasury, tax, accounting, and SEC reporting operations.
  • Prior to joining Nkarta, she held senior leadership roles in finance, accounting and operations at Amunix and OncoMed.